puc57 Search Results


93
Addgene inc 2012 addgene plasmid
2012 Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57+APEX+(Plasmid+%2340306)/pm34534453-300-79-80
Average 93 stars, based on 1 article reviews
2012 addgene plasmid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc puc57 mito lb nox
Puc57 Mito Lb Nox, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-mitoLbNOX+(Plasmid+%2374448)/pmc09120069-326-6-9
Average 93 stars, based on 1 article reviews
puc57 mito lb nox - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Addgene inc puc57 sgrna expression vector
Puc57 Sgrna Expression Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-sgRNA+expression+vector+(Plasmid+%2351132)/10__1161_slash_hypertensionaha__116__08500-16-17-20
Average 95 stars, based on 1 article reviews
puc57 sgrna expression vector - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Addgene inc lbnox
Lbnox, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-LbNOX+(Plasmid+%2375285)/pm37879334-304-5-6
Average 95 stars, based on 1 article reviews
lbnox - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Addgene inc puc57 t7 vector
Puc57 T7 Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-Simple-gRNA+backbone+(Plasmid+%2351306)/pmc04766569-84-8-10
Average 93 stars, based on 1 article reviews
puc57 t7 vector - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc tpnox
PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, <t>TPNOX</t> <t>or</t> <t>mitoTPNOX</t> of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.
Tpnox, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-TPNOX+(Plasmid+%2387853)/pmc12166406-490-0-1
Average 93 stars, based on 1 article reviews
tpnox - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc puc57 plasmid
PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, <t>TPNOX</t> <t>or</t> <t>mitoTPNOX</t> of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.
Puc57 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57+(Gent)+(Plasmid+%2354338)/10__2147_slash_jir__s333725-36-15-14
Average 93 stars, based on 1 article reviews
puc57 plasmid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc addgene plasmid
PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, <t>TPNOX</t> <t>or</t> <t>mitoTPNOX</t> of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.
Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pET259-pUC57+24xMS2V6+(Plasmid+%23104391)/pmc12632079-441-30-30
Average 93 stars, based on 1 article reviews
addgene plasmid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Addgene inc puc57mini vector
PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, <t>TPNOX</t> <t>or</t> <t>mitoTPNOX</t> of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.
Puc57mini Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/IMBB2%2E4-pUC57-mini+(Plasmid+%2388845)/pm39947183-270-28-30
Average 93 stars, based on 1 article reviews
puc57mini vector - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
Addgene inc old c57bl 6j mice
PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, <t>TPNOX</t> <t>or</t> <t>mitoTPNOX</t> of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.
Old C57bl 6j Mice, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-Kan_BR29_00092011+(Plasmid+%23121212)/pmc10752887-71-3-44
Average 91 stars, based on 1 article reviews
old c57bl 6j mice - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

91
Addgene inc puc57 pb pgk tetr 3xflag ha 2a puro plasmid
( A ) The relative expression levels of the PURO r gene normalized to ACTB in the three clones of <t>STITCH/tetR-3xFlag-HA</t> and the five clones of STITCH/KRAB, with and without DOX. We also compared the PURO r expression level in the STITCH+30kb clone with the selection cassette before the Cre induction. ( B ) The MYC expression levels normalized to ACTB in the three STITCH/tetR-3xFlag-HA clones with and without DOX. The MYC expression levels of ancestral Hap and STITCH+30kb clones are also plotted. ( C ) The MYC expression level normalized to ACTB in a del(30-440)/tetR-KRAB clone with and without DOX, together with those in the ancestral Hap and STITCH+30kb clones. ( D ) The relative MYC expression levels of the clone 3 of STITCH/KRAB with different concentrations of DOX. ( E ) The nChIP-seq tracks for H3K9me3 and CTCF with and without DOX. The reads were mapped to a synthetic genomic DNA sequence around the MYC locus with the STITCH insert. The experiments were performed in duplicates (rep1 and rep2). ( F ) The normalized log2 fold changes in STITCH/KRAB without DOX compared to with DOX were calculated for all the peaks of CTCF nChIP-seq. The peaks are ordered according to the rank of the fold change (upper) and also plotted as an MA-plot. ( G ) Magnified views around STITCH of ( E ). ( H ) nChIP-qPCR for CTCF binding at the L2 motif of STITCH in the STITCH/KRAB clone with and without DOX. As the negative and positive controls, the enrichment at T and the binding site near RAE1 was also quantified. ( I ) The CTCF nChIP-seq tracks around RAE1 , and T . ( J ) nChIP-qPCR for CTCF binding at L2, RAE1 , and T in the STITCH/tetR-3xFLAG-HA with and without DOX. ( K ) CTCF nChIP-qPCR at L2, RAE1 , and T in the STITCH+30kb with the PURO r cassette before the Cre recombination. ( L ) The MYC expression level in the STITCH+30kb with the PURO r cassette, compared to the expression level of the Hap clone. ( M ) The 4C-seq tracks in the STITCH/KRAB clone with and without DOX from VP-MYC1 (purple) and VP-MYC2 (blue). The numbers indicate ratios of mapped reads to given intervals within the locally haploid 3 Mb region except for the 10 kb region from the viewpoint fragment. ( N ) Normalized cell numbers after five-days culture with and without DOX. The dots represent replicates, and the bars indicate their means. * indicates p<0.05 by two-sided Welch's two-sample t-test.
Puc57 Pb Pgk Tetr 3xflag Ha 2a Puro Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-PB-PGK-tetR-3xFLAG-HA-2A-Puro+(Plasmid+%23129537)/pmc07200164-28-4-10
Average 91 stars, based on 1 article reviews
puc57 pb pgk tetr 3xflag ha 2a puro plasmid - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

90
Addgene inc puc57 4ecol2a1
( A ) The relative expression levels of the PURO r gene normalized to ACTB in the three clones of <t>STITCH/tetR-3xFlag-HA</t> and the five clones of STITCH/KRAB, with and without DOX. We also compared the PURO r expression level in the STITCH+30kb clone with the selection cassette before the Cre induction. ( B ) The MYC expression levels normalized to ACTB in the three STITCH/tetR-3xFlag-HA clones with and without DOX. The MYC expression levels of ancestral Hap and STITCH+30kb clones are also plotted. ( C ) The MYC expression level normalized to ACTB in a del(30-440)/tetR-KRAB clone with and without DOX, together with those in the ancestral Hap and STITCH+30kb clones. ( D ) The relative MYC expression levels of the clone 3 of STITCH/KRAB with different concentrations of DOX. ( E ) The nChIP-seq tracks for H3K9me3 and CTCF with and without DOX. The reads were mapped to a synthetic genomic DNA sequence around the MYC locus with the STITCH insert. The experiments were performed in duplicates (rep1 and rep2). ( F ) The normalized log2 fold changes in STITCH/KRAB without DOX compared to with DOX were calculated for all the peaks of CTCF nChIP-seq. The peaks are ordered according to the rank of the fold change (upper) and also plotted as an MA-plot. ( G ) Magnified views around STITCH of ( E ). ( H ) nChIP-qPCR for CTCF binding at the L2 motif of STITCH in the STITCH/KRAB clone with and without DOX. As the negative and positive controls, the enrichment at T and the binding site near RAE1 was also quantified. ( I ) The CTCF nChIP-seq tracks around RAE1 , and T . ( J ) nChIP-qPCR for CTCF binding at L2, RAE1 , and T in the STITCH/tetR-3xFLAG-HA with and without DOX. ( K ) CTCF nChIP-qPCR at L2, RAE1 , and T in the STITCH+30kb with the PURO r cassette before the Cre recombination. ( L ) The MYC expression level in the STITCH+30kb with the PURO r cassette, compared to the expression level of the Hap clone. ( M ) The 4C-seq tracks in the STITCH/KRAB clone with and without DOX from VP-MYC1 (purple) and VP-MYC2 (blue). The numbers indicate ratios of mapped reads to given intervals within the locally haploid 3 Mb region except for the 10 kb region from the viewpoint fragment. ( N ) Normalized cell numbers after five-days culture with and without DOX. The dots represent replicates, and the bars indicate their means. * indicates p<0.05 by two-sided Welch's two-sample t-test.
Puc57 4ecol2a1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/puc57/pUC57-4eCOL2A1+(Plasmid+%2397211)/pmc06457328-201-3-11
Average 90 stars, based on 1 article reviews
puc57 4ecol2a1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.

Journal: Redox Biology

Article Title: PRPS activity tunes redox homeostasis in Myc-driven lymphoma

doi: 10.1016/j.redox.2025.103649

Figure Lengend Snippet: PRPS activity governs redox balance (A) Western blot validating CRISPR/Cas9 mediated knockout of PRPS1 and PRPS2 in two separate human Burkitt's lymphoma-derived cell lines, CA46 (left) and DG-75 (right). 24 kDa PARP1 fragment is used as an apoptotic marker. GAPDH used as a loading control. Levels of (B) NADPH and (C) reduced glutathione (GSH) in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines, measured via relative luciferase units (RLU) of luminescent-based GLO-assays. (D) AlamarBlue mean fluorescence intensity (MFI) as a readout of intracellular reduction in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (E) Total intracellular ROS accumulation, measured via CM-H 2 DCFDA MFI and (F) mitochondrial ROS accumulation, measured via MitoSOX Red MFI in WT, PRPS1 KO and PRPS2 KO cells of CA46 (left) and DG-75 (right) cell lines. (G) AlamarBlue MFI as a readout of intracellular reduction in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. (H) Western blot of PARP1 cleavage as an apoptotic marker in WT, PRPS2 KO and PRPS2 KO cells containing exogenously expressed NDI1, AOX, TPNOX or mitoTPNOX of CA46 (left) and DG-75 (right) cell lines. β-Actin used as a loading control. (I) Western blot validating stable exogenous expression of ALFA-tagged PRPS1, PRPS2 and PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) PRPS2 KO cell lines. 24 kDa PARP1 fragment is used as an apoptotic marker. β-Actin used as a loading control. (J) AlamarBlue MFI as a readout of intracellular reduction and (K) MitoSOX Red MFI as a readout of mitochondrial ROS accumulation in WT, PRPS1 KO, PRPS2 KO and PRPS2 KO cells containing stably integrated ALFA-tagged PRPS1, PRPS2, PRPS1 hypomorphic (A87T) and superactive (H193L) mutant constructs in CA46 (left) and DG-75 (right) cell lines. (L) Schematic depicting the escape or trapping of glucose-derived carbons in a PPP cycle, governed via PRPS enzymatic efficiency. For all panels, statistical analysis performed via one-way ANOVA, bars represent mean ± s.d.; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ns: not significant.

Article Snippet: TPNOX (Addgene #87853 [ ]) and mitoTPNOX (Addgene #87854 [ ]) cDNA were amplified with primers to include the C-terminal FLAG epitope tag of each plasmid vector and subsequently cloned into the aforementioned FUGW_blasticidin plasmid assembly via restriction digest using AgeI and EcoRI restriction sites (FUGW_TPNOX-FLAG, FUGW_mitoTPNOX-FLAG).

Techniques: Activity Assay, Western Blot, CRISPR, Knock-Out, Derivative Assay, Marker, Control, Luciferase, Fluorescence, Expressing, Mutagenesis, Construct, Stable Transfection

( A ) The relative expression levels of the PURO r gene normalized to ACTB in the three clones of STITCH/tetR-3xFlag-HA and the five clones of STITCH/KRAB, with and without DOX. We also compared the PURO r expression level in the STITCH+30kb clone with the selection cassette before the Cre induction. ( B ) The MYC expression levels normalized to ACTB in the three STITCH/tetR-3xFlag-HA clones with and without DOX. The MYC expression levels of ancestral Hap and STITCH+30kb clones are also plotted. ( C ) The MYC expression level normalized to ACTB in a del(30-440)/tetR-KRAB clone with and without DOX, together with those in the ancestral Hap and STITCH+30kb clones. ( D ) The relative MYC expression levels of the clone 3 of STITCH/KRAB with different concentrations of DOX. ( E ) The nChIP-seq tracks for H3K9me3 and CTCF with and without DOX. The reads were mapped to a synthetic genomic DNA sequence around the MYC locus with the STITCH insert. The experiments were performed in duplicates (rep1 and rep2). ( F ) The normalized log2 fold changes in STITCH/KRAB without DOX compared to with DOX were calculated for all the peaks of CTCF nChIP-seq. The peaks are ordered according to the rank of the fold change (upper) and also plotted as an MA-plot. ( G ) Magnified views around STITCH of ( E ). ( H ) nChIP-qPCR for CTCF binding at the L2 motif of STITCH in the STITCH/KRAB clone with and without DOX. As the negative and positive controls, the enrichment at T and the binding site near RAE1 was also quantified. ( I ) The CTCF nChIP-seq tracks around RAE1 , and T . ( J ) nChIP-qPCR for CTCF binding at L2, RAE1 , and T in the STITCH/tetR-3xFLAG-HA with and without DOX. ( K ) CTCF nChIP-qPCR at L2, RAE1 , and T in the STITCH+30kb with the PURO r cassette before the Cre recombination. ( L ) The MYC expression level in the STITCH+30kb with the PURO r cassette, compared to the expression level of the Hap clone. ( M ) The 4C-seq tracks in the STITCH/KRAB clone with and without DOX from VP-MYC1 (purple) and VP-MYC2 (blue). The numbers indicate ratios of mapped reads to given intervals within the locally haploid 3 Mb region except for the 10 kb region from the viewpoint fragment. ( N ) Normalized cell numbers after five-days culture with and without DOX. The dots represent replicates, and the bars indicate their means. * indicates p<0.05 by two-sided Welch's two-sample t-test.

Journal: eLife

Article Title: Controlling gene activation by enhancers through a drug-inducible topological insulator

doi: 10.7554/eLife.47980

Figure Lengend Snippet: ( A ) The relative expression levels of the PURO r gene normalized to ACTB in the three clones of STITCH/tetR-3xFlag-HA and the five clones of STITCH/KRAB, with and without DOX. We also compared the PURO r expression level in the STITCH+30kb clone with the selection cassette before the Cre induction. ( B ) The MYC expression levels normalized to ACTB in the three STITCH/tetR-3xFlag-HA clones with and without DOX. The MYC expression levels of ancestral Hap and STITCH+30kb clones are also plotted. ( C ) The MYC expression level normalized to ACTB in a del(30-440)/tetR-KRAB clone with and without DOX, together with those in the ancestral Hap and STITCH+30kb clones. ( D ) The relative MYC expression levels of the clone 3 of STITCH/KRAB with different concentrations of DOX. ( E ) The nChIP-seq tracks for H3K9me3 and CTCF with and without DOX. The reads were mapped to a synthetic genomic DNA sequence around the MYC locus with the STITCH insert. The experiments were performed in duplicates (rep1 and rep2). ( F ) The normalized log2 fold changes in STITCH/KRAB without DOX compared to with DOX were calculated for all the peaks of CTCF nChIP-seq. The peaks are ordered according to the rank of the fold change (upper) and also plotted as an MA-plot. ( G ) Magnified views around STITCH of ( E ). ( H ) nChIP-qPCR for CTCF binding at the L2 motif of STITCH in the STITCH/KRAB clone with and without DOX. As the negative and positive controls, the enrichment at T and the binding site near RAE1 was also quantified. ( I ) The CTCF nChIP-seq tracks around RAE1 , and T . ( J ) nChIP-qPCR for CTCF binding at L2, RAE1 , and T in the STITCH/tetR-3xFLAG-HA with and without DOX. ( K ) CTCF nChIP-qPCR at L2, RAE1 , and T in the STITCH+30kb with the PURO r cassette before the Cre recombination. ( L ) The MYC expression level in the STITCH+30kb with the PURO r cassette, compared to the expression level of the Hap clone. ( M ) The 4C-seq tracks in the STITCH/KRAB clone with and without DOX from VP-MYC1 (purple) and VP-MYC2 (blue). The numbers indicate ratios of mapped reads to given intervals within the locally haploid 3 Mb region except for the 10 kb region from the viewpoint fragment. ( N ) Normalized cell numbers after five-days culture with and without DOX. The dots represent replicates, and the bars indicate their means. * indicates p<0.05 by two-sided Welch's two-sample t-test.

Article Snippet: Recombinant DNA reagent , pUC57-PB-PGK-tetR-3xFLAG-HA-2A-Puro (plasmid) , This paper , AddGene 129537 , A piggyBac transposon vector encoding tetR-3xFLAG-HA-2A-Puro r under the PGK promoter..

Techniques: Expressing, Clone Assay, Selection, Sequencing, Binding Assay

Journal: eLife

Article Title: Controlling gene activation by enhancers through a drug-inducible topological insulator

doi: 10.7554/eLife.47980

Figure Lengend Snippet:

Article Snippet: Recombinant DNA reagent , pUC57-PB-PGK-tetR-3xFLAG-HA-2A-Puro (plasmid) , This paper , AddGene 129537 , A piggyBac transposon vector encoding tetR-3xFLAG-HA-2A-Puro r under the PGK promoter..

Techniques: Binding Assay, Transfection, Construct, Recombinant, Plasmid Preparation, Expressing, Sequencing, CRISPR, Isolation, Purification, Software